Feasibility of prognosis assessment for cancer of unknown primary origin using texture analysis of 18F-fluorodeoxyglucose PET/computed tomography images of largest metastatic lymph node

Cancer of unknown primary origin is not an uncommon clinical state, usually accounting for 2%-7% of all cancer patients. Material and methods: Positron emission tomography and computed tomography (PET/CT) was performed in 17 patients with histologically proven metastatic tumors of unknown primary and negative or inconclusive conventional diagnostic procedures. Results: The study included 17 patients (8 male and 9 female) age from 42 to 76 years. PET / CT has pointed out the probable localization of primary tumors in 10 patients. According histological diagnosis of carcinoma of unknown origin, most common is adenocarcinoma (64.71%). Origin of the primary cancer was found in 72.73% patients with adenocarcinoma 66.67% of respondents with squamocelular carcinoma and 50% of respondents with low differentiated carcinoma. Location of primary cancer was not found in 41.18% of the respondents, including patients with mucinous adenocarcinoma and patients with melanoma. Conclusion: FDG PET/CT demonstrates very good whole-body imaging method in evaluation of patients with unknown primary carcinoma.

Download Full-text

A case of mediastinal lymph node cancer of unknown primary origin discovered in paraneoplastic neurological syndrome and positive for anti-Hu antibodies

The Journal of the Japanese Association for Chest Surgery ◽

10.2995/jacsurg.27.100 ◽

2013 ◽

Vol 27 (1) ◽

pp. 100-105

Author(s):

Shinsaku Ueda ◽

Koichiro Iwanaga ◽

Teppei Wakahara ◽

Masahiro Yoshimura

Keyword(s):

Lymph Node ◽

Mediastinal Lymph Node ◽

Paraneoplastic Neurological Syndrome ◽

Cancer Of Unknown Primary ◽

Unknown Primary ◽

Neurological Syndrome ◽

Primary Origin ◽

Unknown Primary Origin

Download Full-text

A Study on Cervical Lymph Node Metastasis from Cancer of Unknown Primary Origin

Practica Oto-Rhino-Laryngologica ◽

10.5631/jibirin.106.1023 ◽

2013 ◽

Vol 106 (11) ◽

pp. 1023-1026

Author(s):

Takashi Taniyama ◽

Tomonori Sugiyama ◽

Mamika Araki ◽

Kouhei Fukukita ◽

Hiroyuki Yamada ◽

...

Keyword(s):

Lymph Node ◽

Lymph Node Metastasis ◽

Cervical Lymph Node ◽

Cervical Lymph Node Metastasis ◽

Cancer Of Unknown Primary ◽

Unknown Primary ◽

Node Metastasis ◽

Primary Origin ◽

Unknown Primary Origin

Download Full-text

Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules

Experimental and Therapeutic Medicine ◽

10.3892/etm.2011.417 ◽

2011 ◽

Vol 3 (3) ◽

pp. 547-549 ◽

Cited By ~ 2

Author(s):

SHOICHIRO OHTA ◽

YUKIKO CHO ◽

MASAHARU SHIBATA ◽

KIMIHIRO NAGAI ◽

TATSUO IIJIMA ◽

...

Keyword(s):

Intracellular Signaling ◽

Signaling Molecules ◽

Cancer Of Unknown Primary ◽

Molecular Targeting ◽

Unknown Primary ◽

Targeting Therapy ◽

Molecular Targeting Therapy ◽

Primary Origin ◽

Intracellular Signaling Molecules ◽

Unknown Primary Origin

Download Full-text

Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin

Frontiers in Oncology ◽

10.3389/fonc.2021.682665 ◽

2021 ◽

Vol 11 ◽

Author(s):

Murilo Bonatelli ◽

Isabella Fernandes Fornari ◽

Priscila Neves Bernécule ◽

Lara Esquiapatti Pinheiro ◽

Ricardo Filipe Alves Costa ◽

...

Keyword(s):

Overall Survival ◽

Lymph Nodes ◽

Glucose Transporter ◽

Metastatic Cancer ◽

Multivariable Analysis ◽

Cancer Of Unknown Primary ◽

Unknown Primary ◽

Primary Origin ◽

Related Proteins ◽

Unknown Primary Origin

IntroductionCancer of unknown primary origin (CUP) is defined as metastatic cancer without identification of the primary site. Considering that only 15–20% of patients with CUP show a favorable outcome, identifying biomarkers may help improve the clinical management of patients who do not respond well to conventional therapies. In this context, the study of the metabolic profile of CUP may pave the way to establish new biomarkers and/or therapeutic targets; therefore, this study aimed to characterize the expression of metabolism-related proteins in CUP.Materials and MethodsThe expression of monocarboxylate transporters MCT1, MCT2 and MCT4, their chaperone CD147, the glucose transporter GLUT1 and the pH regulator CAIX was evaluated by immunohistochemistry in a series of 118 CUP patients, and the results were associated with the available clinicopathological information.ResultsThe metabolism-related proteins MCT1, MCT4, CD147, GLUT1 and CAIX were expressed in a critical portion of the CUP (approximately 20 to 70%). MCT1 and CD147 were both more frequently expressed in cases with lymph nodes as metastasis dominant sites (p = 0.001) as well as in samples from lymph nodes (p <0.001 and p = 0.002, respectively), while MCT1 expression was more frequently expressed in squamous cell carcinomas (p = 0.045). A higher overall survival was observed in patients with tumors positive for GLUT1 and CAIX expression (p = 0.011 and p = 0.041, respectively), but none of the proteins was an independent prognostic factor for overall survival in multivariable analysis.ConclusionThe results suggest that a portion of CUPs present a hyperglycolytic phenotype, which is associated with higher overall survival.

Download Full-text